Researches and develops new pharmaceutical products for various therapeutic areas. Now — the numbers.
This is an established company with proven profits.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
If every debt were paid off today, $461.5M would still be left in the vault — a solid cushion for hard times.
The market pays 41.5× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
There is $611.8M in the vault; even if every debt were paid off, $461.5M would remain.
It pays out $0.0014 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.12. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 4 years, sales fell about 4% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 42 times its annual profit. Even a small disappointment could hit the price hard.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.